Insulin, Neurogenetics and Memory in Alzheimer's Disease

US Department of Veterans Affairs (VA)

Status and phase: Completed; Phase 2

Conditions: Alzheimer Disease

Treatments: Drug: rosiglitazone

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT00018382

AGCG-012-98S

Details and patient eligibility

About

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Sex: All

Ages: 55 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.